A Study to Assess Efficacy and Safety of Pioglitazone as Add-On Therapy to Imatinib Mesylate in CP-CML Patients in Major Molecular Response
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Imatinib (Primary) ; Pioglitazone (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ACTIM
- 22 Sep 2016 New trial record